Xcout IntelObsidian Therapeutics, Inc.
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Subscribe to see Obsidian Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Obsidian Therapeutics, Inc. at a glance
Obsidian Therapeutics, Inc. is a biotechnology company headquartered in Cambridge, United States. It is publicly listed (OBX) with a market capitalisation of $13.6M. Xcout tracks 13 named people at Obsidian Therapeutics, Inc., including Madan Jagasia (President, CEO & Director). Xcout recorded 33 job postings from Obsidian Therapeutics, Inc. in the last 90 days, naming tools such as ADP, NetSuite, SAP.
Obsidian Therapeutics, Inc. leadership
- Madan JagasiaPresident, CEO & Director
- Julie FederChief Financial Officer
- Dana AlexanderChief Technical Officer
- Parameswaran HariChief Medical Officer
- Jennifer H. PetersonChief People Officer
- Maria FardisExecutive Chairman of the Board
7 more named people on record for Obsidian Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Obsidian Therapeutics, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $160.5M | 13 named | |
| — | $115M | — | |
| Series A | $49.5M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Obsidian Therapeutics, Inc.
Xcout recorded 33 job postings from Obsidian Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since July 2026.
Tools named in Obsidian Therapeutics, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Obsidian Therapeutics, Inc.'s hiring signals →
Recent Obsidian Therapeutics, Inc. news
8 corporate events on record, with sources — see the full timeline →
Investors
Tech stack
Obsidian Therapeutics, Inc. competitors
A few of Obsidian Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.
Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative technology platforms and first-in-class T-cell therapies to access cancer-specific targets.
ArsenalBio is a biotechnology company developing programmable cell therapies, particularly engineered T-cell therapies, for cancer treatment. It serves biopharmaceutical and healthcare markets by using synthetic biology and genomic engineering to create more effective, controllable immune-cell medicines.
Kite Pharma is a biopharmaceutical company that develops and manufactures custom CAR T-cell therapies to treat certain types of blood cancer. The company utilizes patients' own engineered immune cells to target and attack cancer, serving patients diagnosed with conditions such as lymphomas.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Get Obsidian Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Obsidian Therapeutics, Inc. in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 8 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access